Treatment Advances for Mismatch Repair Deficient Colon Cancer and Lynch Syndrome

In this episode of Weill Cornell Medicine CancerCast, Dr. Manish Shah hosts Dr. Frank Sinicrope and Dr. Steven Lipkin to discuss advances in managing mismatch repair deficient colon cancer. The discussion covers the prevalence and characteristics of these tumors, the role of immunotherapy as a standard treatment, and the implications of Lynch syndrome. They explore the ATOMIC trial results, which led to the use of Folfox plus atezolizumab for stage 3 and high-risk stage 2 colon cancer, and delve into the potential of neoadjuvant immunotherapy based on the NICHE-2 trial. The panel also addresses resistance to immunotherapy, future therapies like Werner helicase inhibitors and vaccines, and the importance of immune monitoring for sustained immunity.